Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275103 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 355
- Enrollment target
NCT03275103 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 355 participants.
The verdict
NCT03275103, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 355 participants
- Enrollment target
Study Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Interventions
- DRUG Tocilizumab
- DRUG Cevostamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275103
The ClinicalTrials.gov registry entry for NCT03275103 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tocilizumab is the first listed.
NCT03275103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275103 about?
NCT03275103 is a clinical study titled "Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)". This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
What is the current status of trial NCT03275103?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 355 participants. The study started on 2017-09-19. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT03275103?
The interventions under investigation include: Tocilizumab (DRUG), Cevostamab (DRUG).
Who is sponsoring clinical trial NCT03275103?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.